Page 2 - Nawan Butt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

3 Min Read (Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment. FILE PHOTO: A marijuana leaf is displayed at a medical marijuana dispensary in Seattle, Washington, in a file photo. REUTERS/Anthony Bolante GW Pharma’s Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 ...

Creso Pharma Rides Cannabis Stock Momentum –The below is a company-sponsored announcement– Momentum for cannabis stocks continues to intensify, as international acceptance instils confidence in companies to develop and distribute legal products. The confidence in the market was highlighted on Wednesday this week, when GW Pharmaceuticals Ltd. GWPH, announced it was being acquired by Jazz Pharmaceuticals PLC JAZZ in a $7 billion deal. GW develops Epidiolex, a drug that won US Food and Drug Administration approval as a treatment for severe forms of childhood epilepsy in 2018, while JAZZ i...

3 Min Read (Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment. FILE PHOTO: A marijuana leaf is displayed at a medical marijuana dispensary in Seattle, Washington, in a file photo. REUTERS/Anthony Bolante GW Pharma’s Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 ...

3 Min Read (Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment. FILE PHOTO: A marijuana leaf is displayed at a medical marijuana dispensary in Seattle, Washington, in a file photo. REUTERS/Anthony Bolante GW Pharma’s Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 ...

BENGALURU/NEW YORK (Feb 3): Jazz Pharmaceuticals Plc said on Wednesday that it had agreed to buy GW Pharmaceuticals plc in a US$7.2 billion cash-and-stock deal which will bolster its neuroscience business, with the addition of a cannabis-based epilepsy treatment. GW Pharma's Epidiolex, the first marijuana-derived drug to be approved in the US, generated sales of over US$500 million for the UK-based company last year. Analysts expect sales to breach US$1 billion soon. The drug was approved in June 2018 for use in patients aged two years and older with rare childhood-onset forms of epilepsy tha...